Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

467 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?
Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Hollister LE, et al. J Clin Pharmacol. 1981 Aug-Sep;21(S1):171S-177S. doi: 10.1002/j.1552-4604.1981.tb02593.x. J Clin Pharmacol. 1981. PMID: 6271822
It is unlikely that a range of plasma concentrations can be reliably equated with impaired performance. The mode of administration will become important should THC or some homolog become a therapeutic agent....
It is unlikely that a range of plasma concentrations can be reliably equated with impaired performance. The mode of administration wi …
Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse.
Ohlsson A, Widman M, Carlsson S, Ryman T, Strid C. Ohlsson A, et al. Acta Pharmacol Toxicol (Copenh). 1980 Oct;47(4):308-17. doi: 10.1111/j.1600-0773.1980.tb03660.x. Acta Pharmacol Toxicol (Copenh). 1980. PMID: 6258385
All cannabinoids except delta 6-THC and 1"-hydroxy-delta 6-THC showed a very good correlation between brain/plasma concentrations and cataleptic effect. 4"-Hydroxy-and "1-hydroxy-delta 6-THC reached the highest concentration in the brain but the most potent cannabinoids we …
All cannabinoids except delta 6-THC and 1"-hydroxy-delta 6-THC showed a very good correlation between brain/plasma concentrations and …
Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.
Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Lindgren JE, et al. Psychopharmacology (Berl). 1981;74(3):208-12. doi: 10.1007/BF00427095. Psychopharmacology (Berl). 1981. PMID: 6267648 Clinical Trial.
delta 9-Tetrahydrocannabinol (delta 9-THC) was administered in a crossover design by smoking and IV injection to groups of heavy and light users of marihuana. ...To achieve a maximum desired "high", both groups smoked similar amounts (about 13 mg) of delta 9-THC. He …
delta 9-Tetrahydrocannabinol (delta 9-THC) was administered in a crossover design by smoking and IV injection to groups of heavy and …
Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users.
Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Biomed Mass Spectrom. 1982 Jan;9(1):6-10. doi: 10.1002/bms.1200090103. Biomed Mass Spectrom. 1982. PMID: 6277407
Thus, it seems likely that the statistically significant difference in systemic availability of smoked delta 1-tetrahydrocannabinol was due to a more efficient smoking by the heavy users. ...Based on the area under curve values after i.v. administration, a plasma cl …
Thus, it seems likely that the statistically significant difference in systemic availability of smoked delta 1-tetrahydrocannabinol was due …
Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Clin Pharmacol Ther. 1980 Sep;28(3):409-16. doi: 10.1038/clpt.1980.181. Clin Pharmacol Ther. 1980. PMID: 6250760
Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%. Of the two major clinical signs of cannabis intoxication, reddened conjunctivae persisted for as long as THC levels were above 5 ng/ml, and tachycardia was a less reliable measurement of prev …
Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%. Of the two major clinical signs of cannabis intoxication, …
Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.
Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Agurell S, et al. Experientia. 1981 Oct 15;37(10):1090-2. doi: 10.1007/BF02085029. Experientia. 1981. PMID: 6273208 No abstract available.
Detection and quantification of tetrahydrocannabinol in blood plasma.
Ohlsson A, Lindgren JE, Leander K, Agurell S. Ohlsson A, et al. NIDA Res Monogr. 1976 May;(7):48-63. NIDA Res Monogr. 1976. PMID: 967240 No abstract available.
Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking.
Johansson E, Ohlsson A, Lindgren JE, Agurell S, Gillespie H, Hollister LE. Johansson E, et al. Biomed Environ Mass Spectrom. 1987 Sep;14(9):495-9. doi: 10.1002/bms.1200140904. Biomed Environ Mass Spectrom. 1987. PMID: 2960395
467 results
Jump to page
Feedback